Unsupervised machine learning for multi-system adverse event pattern detection in pharmacovigilance: A proof-of-concept analysis of fluoroquinolone reports in FAERS.
Niaz Chalabianloo, Sheikh S Abdullah, Kamran Sedig, Flory T Muanda
{"title":"Unsupervised machine learning for multi-system adverse event pattern detection in pharmacovigilance: A proof-of-concept analysis of fluoroquinolone reports in FAERS.","authors":"Niaz Chalabianloo, Sheikh S Abdullah, Kamran Sedig, Flory T Muanda","doi":"10.1002/bcp.70853","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Traditional pharmacovigilance detects single drug-event associations but cannot readily characterize multi-system adverse-event patterns such as fluoroquinolone-associated disability. We evaluated unsupervised machine learning for this purpose, using fluoroquinolones as an exemplar.</p><p><strong>Methods: </strong>We analysed 40 127 adult fluoroquinolone primary-suspect reports from the FDA Adverse Event Reporting System (FAERS, 2004-2025). Events were encoded as binary MedDRA Preferred Term (PT) and System Organ Class matrices; seriousness and outcome were excluded from clustering and used only post hoc. Multiple correspondence analysis with k-means was primary, validated by k-modes and hierarchical clustering. Cluster number (k = 2-15) was assessed by internal validity indices with bootstrap stability. Comparators were macrolides (n = 39 948) and amoxicillin (n = 16 310).</p><p><strong>Results: </strong>At PT level, silhouette and Calinski-Harabasz indices were optimal at two clusters (Davies-Bouldin at three; silhouette 0.560), separating a multi-system cluster (4072 reports; 10.1%) enriched for neuropsychiatric, musculoskeletal and sensory terms (lifts: memory impairment 8.6, muscle atrophy 8.3, dry eye 7.8). Excluding seriousness and outcome left the cluster essentially unchanged (91.4% retained; κ 0.95), indicating definition by event topology, not case severity; independent algorithms recovered the same subgroup across granularities. Post hoc, the cluster was disproportionately disabling (43.0% vs. 11.7%). The fixed signature classified 14.9% of fluoroquinolone reports vs. 5.3% (macrolides) and 3.9% (amoxicillin).</p><p><strong>Conclusions: </strong>Unsupervised clustering of FAERS data identified, without prior clinical input, a reproducible multi-system adverse-event pattern among fluoroquinolone reports, potentially supporting the feasibility of unsupervised exploratory pattern detection in pharmacovigilance. Given the limitations of spontaneous reporting databases, the findings are strictly hypothesis-generating.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/bcp.70853","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Traditional pharmacovigilance detects single drug-event associations but cannot readily characterize multi-system adverse-event patterns such as fluoroquinolone-associated disability. We evaluated unsupervised machine learning for this purpose, using fluoroquinolones as an exemplar.
Methods: We analysed 40 127 adult fluoroquinolone primary-suspect reports from the FDA Adverse Event Reporting System (FAERS, 2004-2025). Events were encoded as binary MedDRA Preferred Term (PT) and System Organ Class matrices; seriousness and outcome were excluded from clustering and used only post hoc. Multiple correspondence analysis with k-means was primary, validated by k-modes and hierarchical clustering. Cluster number (k = 2-15) was assessed by internal validity indices with bootstrap stability. Comparators were macrolides (n = 39 948) and amoxicillin (n = 16 310).
Results: At PT level, silhouette and Calinski-Harabasz indices were optimal at two clusters (Davies-Bouldin at three; silhouette 0.560), separating a multi-system cluster (4072 reports; 10.1%) enriched for neuropsychiatric, musculoskeletal and sensory terms (lifts: memory impairment 8.6, muscle atrophy 8.3, dry eye 7.8). Excluding seriousness and outcome left the cluster essentially unchanged (91.4% retained; κ 0.95), indicating definition by event topology, not case severity; independent algorithms recovered the same subgroup across granularities. Post hoc, the cluster was disproportionately disabling (43.0% vs. 11.7%). The fixed signature classified 14.9% of fluoroquinolone reports vs. 5.3% (macrolides) and 3.9% (amoxicillin).
Conclusions: Unsupervised clustering of FAERS data identified, without prior clinical input, a reproducible multi-system adverse-event pattern among fluoroquinolone reports, potentially supporting the feasibility of unsupervised exploratory pattern detection in pharmacovigilance. Given the limitations of spontaneous reporting databases, the findings are strictly hypothesis-generating.
期刊介绍:
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.